

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GC Construction Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1489)

(1) APPOINTMENT OF EXECUTIVE DIRECTOR; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Director(s)**”) of GC Construction Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that (i) Ms. Chan Chui Ying (“**Ms. Chan**”) has been appointed as an executive Director; and (ii) Dr. Luk Che Chung, *JP* (“**Dr. Luk**”) has been appointed as an independent non-executive Director, both with effect from 5 February 2024.

APPOINTMENT OF EXECUTIVE DIRECTOR

Ms. Chan has been appointed as an executive Director with effect from 5 February 2024. The biographical details of Ms. Chan are as follows:

Ms. Chan Chui Ying (陳翠盈小姐), aged 28, has been the corporate promotion, administration and human resources manager of the Group since February 2018 and has been responsible for the sales and marketing and administration of the Group. Ms. Chan is the daughter of Mr. Chan Kiu Sum, being the chairman of the Board, the chief executive officer of the Group and an executive Director, and a niece of Mr. Chan Wing Ping, being an executive Director.

Ms. Chan has over 5 years of experience in sales and marketing. Ms. Chan was an account executive of Ginger Advertising Limited from September 2015 to June 2016. She worked at Meitu (China) Limited as a marketing and public relations executive from June 2016 to February 2018.

Ms. Chan graduated from Pierce College in Washington, the United States, with an associate’s degree of arts in June 2013. She then obtained a bachelor’s degree of arts in communication from the University of Washington in the United States in June 2015. In October 2019, Ms. Chan completed the online credential of readiness program in business analytics, economics for managers and financial accounting organised by Harvard Business School. Ms. Chan completed (a) a 43-hour programme of construction safety supervisors in August 2022; and (b) a 52-hour course in construction specialist trades management and a 21-hour course in project management training series for sub-contractors in November 2021, both organised by the Hong Kong Institute of Construction.

Ms. Chan has entered into a service agreement with the Company for acting as an executive Director for an initial term of three years commencing from 5 February 2024, which shall be renewed and extended automatically by three years on the expiry of the initial term and on the expiry of every successive period of three years thereafter and is terminable by either party by giving no less than three months' prior notice, subject to rotation, removal, vocation, termination, retirement and re-election in accordance with the provisions of the articles of association of the Company (the "**Articles**"). Ms. Chan is subject to retirement by rotation and re-election in accordance with the Articles. Ms. Chan is entitled to a director's fee of HKD540,800 per annum and discretionary bonus, which is determined by the Board with reference to her experience, qualification, duties and responsibilities in the Company and the prevailing market conditions. She is also entitled to be reimbursed for all necessary and reasonable out-of-pocket expenses properly incurred in connection with the performance of her duties to the Company.

As at the date of this announcement, Ms. Chan does not have, and/or is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

Ms. Chan has confirmed that, as at the date of this announcement and save as disclosed above, she (i) has not been a director in any other listed companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years prior to the date of this announcement; (ii) does not have any other major appointments and professional qualifications; (iii) does not hold any other positions with the Company or other subsidiaries of the Company; and (iv) does not have any relationship with any other Directors, senior management members, substantial shareholders or controlling shareholders of the Company (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")).

Ms. Chan has confirmed that, save as disclosed above, there is no other information relating to her appointment that is required to be disclosed pursuant to Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Listing Rules and there is no other matter relating to her appointment that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and the Stock Exchange.

The Board would like to express its warmest welcome to Ms. Chan for joining the Board.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Dr. Luk has been appointed as an independent non-executive Director with effect from 5 February 2024. The biographical details of Dr. Luk are as follows:

Dr. Luk Che Chung (陸志聰醫生), aged 62, is among the first batch of medical graduates from the Chinese University of Hong Kong in 1986. He holds a master's degree of public administration from the University of Hong Kong. Dr. Luk is also the Member of Faculty of Public Health since 2016. He has been a healthcare executive in the public sector since 1990 with a wide range of exposure and track record in managing complex and large healthcare systems, crisis management, human resources management, corporate governance, corporate communications and media management, quality and risk management and business development. He has solid experiences of working with senior professionals, media and regulatory bodies, government officials, politicians and people on all fronts, both inside and outside the healthcare sector.

During his 10 years of services at the Hospital Authority Head Office, Dr. Luk was responsible for the annual planning of overall operations, service and facilities planning, development of specialist clinical services, liaison with the social sector and community, hospital operations and quality management.

Dr. Luk is currently the vice-chairman of Virtus Medical Group Limited. Since 1999, Dr. Luk worked as a hospital chief executive, managing various public hospitals at different times, the main ones being Kwong Wah Hospital, United Christian Hospital and Queen Mary Hospital. Since 2005, he also served as the cluster chief executive of Kowloon East Cluster for 4 years and then Hong Kong West Cluster for 9 years. Dr. Luk was appointed as the cluster chief executive of Hong Kong East Cluster and the hospital chief executive of Pamela Youde Nethersole Eastern Hospital, Wong Chuk Hang Hospital and St. John Hospital in October 2018. He was responsible for the management of 9,000 staff with a recurrent budget of over HK\$8 billion, and the operation of seven hospitals and 12 general outpatient clinics providing acute and comprehensive medical services to a population of 0.8 million. In November 2021, Dr. Luk retired from the Hospital Authority. He worked as the deputy chief executive officer for Your Health Specialists Medical Group Limited from November 2021 to September 2022. In September 2023, Dr. Luk was appointed as an independent non-executive director of ECI Technology Holdings Limited, a company listed on GEM of the Stock Exchange (stock code: 8013).

Over the years, Dr. Luk has been involved in various community work, including the Medical Council, The Community Chest of Hong Kong, The Hong Kong Council of Social Service, other various community and non-governmental organisations, and teaching in some tertiary institutions.

In recent years, Dr. Luk has been directly involved in the Community Housing Movement and the Modular Housing Initiative. Dr. Luk was appointed as a Justice of the Peace by the Hong Kong SAR Government in 2019, and received the Distinguished Medical Alumni Award from the Faculty of Medicine of the Chinese University of Hong Kong in 2020.

Dr. Luk has entered into an appointment letter with the Company for a term of one year commencing from 5 February 2024, which shall be renewed and extended automatically by one year on the expiry of the initial term and on the expiry of every successive period of one year thereafter and is terminable by either party by giving no less than three months' prior notice, subject to rotation, removal, vocation, termination, retirement and re-election in accordance with the provisions of the Articles. Dr. Luk will hold office until the next general meeting of the Company after his appointment and shall then be eligible for re-election at that meeting, thereafter subject to retirement by rotation at least once every three years at each annual general meeting in accordance with the Articles. Dr. Luk is subject to retirement by rotation and re-election in accordance with the Articles. Dr. Luk is entitled to a director's annual fee of HK\$180,000 as an independent non-executive Director. The emolument of Dr. Luk has been determined by the remuneration committee of the Board with reference to his skill, knowledge and experience, his duties and responsibilities with the Company, the Company's performance and the prevailing market conditions.

As at the date of this announcement, Dr. Luk is interested in 670,000 shares of the Company, representing approximately 0.067% of the total issued shares of the Company.

Dr. Luk has confirmed that, as at the date of this announcement and save as disclosed above, he (i) has not been a director in any other listed companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years prior to the date of this announcement; (ii) does not have any other major appointments and professional qualifications; (iii) does not hold any other positions with the Company or other subsidiaries of the Company; (iv) does not have any relationship with any other Directors, senior management members, substantial shareholders or controlling shareholders of the Company (as defined in the Listing Rules); and (v) does not have, and/or is deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the SFO.

Dr. Luk has confirmed that (i) he meets the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Dr. Luk has confirmed that, save as disclosed above, there is no other information relating to his appointment that is required to be disclosed pursuant to Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Listing Rules and there is no other matter relating to her appointment that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to express its warmest welcome to Dr. Luk for joining the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following Dr. Luk's appointment, Dr. Luk has been appointed as a member of each of the audit committee, nomination committee and remuneration committee of the Company.

On behalf of the Board
GC Construction Holdings Limited
Chan Kiu Sum
Chairman and Executive Director

Hong Kong, 5 February 2024

As at the date of this announcement, the Board comprises Mr. Chan Kiu Sum (Chairman and Chief Executive Officer), Mr. Chan Wing Ping and Ms. Chan Chui Ying as executive Directors and Dr. Huang Hong, Mr. Yu Chi Wing, Dr. Lo Ki Chiu and Dr. Luk Che Chung, JP, as independent non-executive Directors.